EAS Journal of Pharmacy and Pharmacology
Abbreviated Key Title: EAS J Pharm Pharmacol
ISSN: 2663-0990 (Print) & ISSN: 2663-6719 (Online)
Published By East African Scholars Publisher, Kenya

OPEN ACCESS

Volume-5 | Issue-6 | Nov-Dec- 2023 |

DOI: 10.36349/easjpp.2023.v05i06.002

Original Research Article

Pharmacists as Frontline Health Educators: Strategies for Hypertension and Cardiovascular Disease Prevention

Hudallah Oluwakemi Adetola-Kazeem[1*], Chinwe Ann ILOABANAFO[2], Sakiru Ayobami Hamzat[3], Latifat Abolore Igbin[4]

[1]University of Lagos, Nigeria
[2]University of Nigeria, Nsukka – Enugu State
[3]Emmanuel Alayande University of Education, Oyo, Nigeria
[4]Tallinn University, Estonia

Article History
Received: 16.10.2023
Accepted: 17.12.2023
Published: 25.12.2023

Journal homepage:
https://www.easpublisher.com

Quick Response Code

Abstract: Hypertension and cardiovascular disease remain leading causes of mortality worldwide, with prevention and early detection essential for reducing their burden. Pharmacists, as highly accessible healthcare professionals, are increasingly recognized as frontline educators who contribute to both awareness and management. This study synthesizes evidence from randomized controlled trials, systematic reviews, and policy frameworks to evaluate the role of pharmacists in lifestyle counseling, screening, and integrated care for hypertension prevention. Findings confirm that pharmacist-led interventions can significantly reduce blood pressure, enhance medication adherence, and identify undiagnosed cases. Evidence also shows that the most successful outcomes emerge when pharmacists are integrated into multidisciplinary teams and supported through structured training, digital monitoring, and policy frameworks. Future directions highlight the importance of embedding scalable digital systems for accountability and incorporating psychosocial sensitivity into pharmacist practice to strengthen equity and trust in cardiovascular prevention.

Keywords: Pharmacists, Hypertension, Cardiovascular Disease, Lifestyle Education, Screening.

INTRODUCTION

Hypertension remains one of the leading modifiable risk factors for cardiovascular disease (CVD), which continues to be the foremost cause of morbidity and mortality worldwide. The World Health Organization (WHO, 2021) estimates that over 1.2 billion adults live with hypertension globally, with a disproportionately high burden in low- and middle-income countries where health systems face resource constraints. Despite the availability of effective antihypertensive medicines, control rates remain suboptimal, often due to low awareness, poor adherence, and limited access to preventive services (Mills *et al.,* 2016). In this context, pharmacists have emerged as critical frontline health educators, positioned uniquely to address both detection gaps and lifestyle risk factors through community engagement. Evidence from international systematic reviews has underscored the effectiveness of pharmacist-led interventions in improving blood pressure outcomes. A Cochrane review by Glynn *et al.,*(2010) demonstrated that pharmacist involvement in hypertension management resulted in significantly improved blood pressure control compared to usual care. Similarly, a meta-analysis by Santschi *et al.,*(2014) found that structured pharmacist interventions, including medication reviews and patient education, resulted in mean systolic blood pressure reductions of 7–9 mmHg, representing a clinically meaningful improvement. These findings confirm that pharmacists not only dispense medications but also play a transformative role in preventing chronic diseases.

The importance of pharmacist-led education extends beyond pharmacological management. Trials, such as those conducted by Machado *et al.,*(2007) and Morgado *et al.,*(2011), demonstrate that pharmacists' counseling on lifestyle changes, smoking cessation, salt reduction, and physical activity has a measurable impact on cardiovascular risk factors. Unlike physicians, pharmacists often have more frequent interactions with patients in the community, enabling ongoing education, reinforcement of healthy behaviors, and early detection of uncontrolled hypertension (Morgado *et al.,* 2011). This positions pharmacists as accessible educators who

***Corresponding Author:** Hudallah Oluwakemi Adetola
University of Lagos, Nigeria

can bridge the gap between public health messaging and individualized patient support. National and international policy frameworks increasingly support this expanded role. The National Institute for Health and Care Excellence (NICE, 2019) recommends that pharmacists contribute to the detection and management of hypertension through opportunistic blood pressure checks, structured education, and referral pathways. The WHO Global Hearts Initiative (2018) similarly emphasizes task-shifting approaches that integrate pharmacists into frontline CVD prevention strategies. These endorsements underscore the growing recognition that strengthening the health system requires maximizing the roles of all healthcare professionals, particularly those embedded in communities.

Despite such recognition, challenges remain. Studies highlight barriers including limited training in behavioral counseling, insufficient remuneration for extended services, and resistance from other health professionals who question pharmacists' scope of practice (Hajjar *et al.,* 2014). Addressing these challenges requires evidence-informed policy reforms and innovative models of interprofessional collaboration. The integration of digital tools, such as telemonitoring apps and electronic health records, may further enhance pharmacists' capacity to deliver personalized education and facilitate continuity of care (Pittman *et al.,* 2019). The introduction of pharmacist-led education into hypertension and CVD prevention frameworks reflects both necessity and opportunity. As evidence accumulates, it is increasingly evident that pharmacists can deliver measurable improvements in blood pressure, enhance patient knowledge and adherence, and promote lifestyle changes critical to cardiovascular health. However, realizing this potential requires addressing systemic barriers, fostering collaboration, and embedding pharmacists within structured prevention programs. This study, therefore, aims to explore the strategies, challenges, and future directions of pharmacists as frontline health educators in hypertension and CVD prevention.

OBJECTIVES

1. To explore pharmacist-led health education strategies for hypertension and CVD prevention.
2. To examine the effectiveness of pharmacist interventions in improving blood pressure control and lifestyle outcomes.
3. To analyze barriers and enablers of implementing pharmacist-led education in community settings.
4. To identify evidence-based strategies for sustainable pharmacist involvement in CVD prevention.

RELATED WORK

A large body of research supports the contribution of pharmacists in the detection, education, and management of hypertension and cardiovascular disease. Randomized controlled trials and systematic reviews have consistently demonstrated that pharmacist interventions are associated with improved blood pressure control, increased adherence, and enhanced patient engagement in self-care. For example, Glynn *et al.,*(2010) reported that pharmacist involvement in hypertension management achieved superior outcomes compared to usual physician care. Similarly, Santschi *et al.,*(2014) found that pharmacist-led programs resulted in reductions in systolic blood pressure of 7 to 9 mmHg, a change with significant implications for reducing the incidence of cardiovascular events. Several reviews reinforce this trend. Carter *et al.,*(2009) demonstrated that collaborative pharmacist care significantly reduced both systolic and diastolic blood pressure. Cheema *et al.,*(2014) confirmed that pharmacist interventions consistently outperformed routine care across diverse settings. Tan *et al.,*(2016) provided further evidence that structured educational support from pharmacists improved long-term adherence and clinical outcomes. Khaira *et al.,*(2020) extended this evidence base by demonstrating that pharmacist involvement yields sustained reductions in blood pressure, highlighting its potential in long-term chronic disease management. In addition to lowering blood pressure, pharmacists have been shown to improve medication adherence. Morgado *et al.,*(2011) demonstrated that pharmacist counseling programs increased adherence and improved control rates in hypertensive patients. Machado *et al.,*(2007) provided evidence that pharmacist interventions significantly enhanced patient adherence to antihypertensive regimens, underscoring the importance of education and counseling as core components of pharmacy practice. The role of pharmacists also extends to the early detection of hypertension. Tsuyuki *et al.,*(2015) demonstrated that community pharmacists in Canada successfully identified patients with undiagnosed hypertension and facilitated their referral for treatment. Al Hamarneh *et al.,*(2013) provided similar evidence from Jordan, demonstrating that pharmacist-led detection and education programs resulted in significant improvements in blood pressure outcomes. Fikri Benbrahim *et al.,*(2019) and Albasri *et al.,*(2020) confirmed this trend in Morocco, where community pharmacists effectively supported both early detection and lifestyle modification counseling.

Policy frameworks have responded by endorsing greater pharmacist involvement in the prevention of cardiovascular disease. The World Health Organization Global Hearts Initiative (2018) advocates for the integration of pharmacists in primary prevention strategies. Similarly, the National Institute for Health and Care Excellence (2019) recommends that pharmacists conduct opportunistic blood pressure checks, provide structured education, and establish referral pathways with general practitioners. These endorsements reflect broader recognition of pharmacists as essential contributors to population health. Despite this evidence,

challenges remain. Hajjar *et al.,*(2014) reported that limited training in behavioral counseling constrains the effectiveness of some interventions. Pittman *et al.,*(2019) observed that fragmented communication between pharmacists and primary care physicians' results in reduced continuity of care. Whelton *et al.,*(2018) suggested that systemic enablers, such as the integration of electronic health records, pharmacist training, and appropriate remuneration, can overcome many of these barriers. Together, these findings underscore the significance of structural and systemic support in empowering pharmacists to realize their full potential in cardiovascular disease prevention.



Diagram 1. Global Trends in Pharmacist-Led Hypertension Interventions ***(Comparative systolic blood pressure reductions reported in Glynn et al., 2010; Santschi et al., 2014; Carter et al., 2009; and Tan et al., 2016, highlighting superior outcomes in pharmacist-led programs compared to routine care.)***

METHODOLOGY

This study employs a qualitative synthesis approach to critically evaluate secondary evidence on pharmacist-led interventions for preventing hypertension and cardiovascular disease. Rather than producing new empirical data, the analysis relies on systematically selected peer-reviewed studies, policy frameworks, and meta-analyses that assess the role of pharmacists in prevention, education, and early detection. This approach is appropriate because the body of existing literature is both extensive and contested, requiring careful integration rather than replication. The inclusion criteria focused on studies that evaluated pharmacist involvement in hypertension management, with a particular emphasis on outcomes related to blood pressure control, medication adherence, lifestyle modification, and patient education. Systematic reviews, randomized controlled trials, and national or international guidelines were prioritized due to their rigor and generalizability. Studies from both high-income and low- and middle-income settings were included in order to capture variations in practice across different healthcare systems. Conversely, studies that exclusively addressed pharmacological treatment without an educational or preventive dimension were excluded, as the focus here lies in pharmacists' roles beyond medicine dispensing. Data analysis involved thematic synthesis, identifying recurring patterns in evidence relating to three primary domains: prevention through education and lifestyle counseling, detection through screening and referral pathways, and long-term management of hypertension within integrated care models. Attention was given to methodological quality, with risk of bias assessments drawn from systematic reviews, such as those by Glynn *et al.,*(2010) and Santschi *et al.,*(2014). Where conflicting results were present, such as differences in adherence outcomes, the analysis highlighted not only the reported findings but also the contextual and methodological factors influencing them. Through this structured review and synthesis, the methodology provides a robust framework for examining the contribution of pharmacists as frontline educators and identifying evidence gaps that warrant further investigation.

Core Section: The Pharmacists' Role in CVD Prevention

Lifestyle Education and Counseling

The role of pharmacists in providing lifestyle education has become increasingly central to the global response to hypertension and cardiovascular disease prevention. Evidence indicates that non-pharmacological interventions such as smoking cessation, dietary modification, weight control, and increased physical activity are essential complements to drug therapy in reducing cardiovascular risk (Mills *et al.,* 2016). Pharmacists, due to their accessibility and frequency of contact with patients, are uniquely positioned to

reinforce these preventive messages and provide individualized counseling. Multiple studies have demonstrated the effectiveness of pharmacist-led counseling in supporting lifestyle changes. Machado *et al.,*(2007) reported that structured pharmacist consultations significantly improved patient adherence to dietary and exercise recommendations, contributing to reductions in blood pressure. Morgado *et al.,*(2011) similarly found that pharmacist education programs in Portugal led to improved knowledge of hypertension risk factors and greater engagement with self-care practices. These findings highlight the pharmacist's potential not only as a medicine expert but also as a facilitator of behavioral change. Educational interventions often employ structured approaches that combine verbal counseling with written materials and follow-up support. Glynn *et al.,*(2010) emphasized the effectiveness of repeated pharmacist-patient interactions in reinforcing adherence to strategies for reducing salt intake and managing weight. In Morocco, Fikri Benbrahim *et al.,*(2019) demonstrated that pharmacists were able to engage patients in culturally appropriate counseling sessions that improved lifestyle behaviors, showing that interventions can be adapted to resource-constrained environments.

Digital tools increasingly complement these efforts. Pittman *et al.,*(2019) highlighted the role of mobile health applications and telemonitoring in supporting patients with hypertension, enabling pharmacists to track adherence and provide feedback remotely. This integration of technology enhances the reach and sustainability of pharmacist-led counseling, especially in rural or underserved areas. Despite these successes, barriers remain. Hajjar *et al.,*(2014) and Albasri *et al.,*(2020) identified limited training in motivational interviewing and behavioral counseling as a constraint on pharmacists' capacity to influence lifestyle behaviors. Additionally, structural issues such as a lack of remuneration for extended counseling services limit widespread implementation (Tsuyuki *et al.,* 2015; Albasri *et al.,* 2020). Addressing these challenges requires systemic reforms, including recognition of pharmacists' preventive roles within reimbursement structures and integration into primary care teams. Policy frameworks underscore the importance of pharmacist involvement in lifestyle education. The National Institute for Health and Care Excellence (2019) recommends that community pharmacists actively support smoking cessation and dietary modification programs as part of hypertension prevention. Similarly, the World Health Organization (2018) emphasizes lifestyle counseling as a cornerstone of cardiovascular disease prevention, highlighting pharmacists as key players in delivering this service at the community level. These endorsements emphasize that lifestyle education is not ancillary but fundamental to the success of hypertension management programs.



Diagram 2: Flowchart of Pharmacist–Patient Education Pathway in Hypertension Prevention

Lifestyle education and counseling provided by pharmacists have demonstrated measurable benefits in the prevention of hypertension and cardiovascular disease. While challenges in training, funding, and system integration persist, the evidence suggests that pharmacist-led interventions can effectively promote healthier behaviors, lower blood pressure, and empower patients to take greater responsibility for their cardiovascular health.

Screening and Early Detection Strategies

Screening and early detection of hypertension and related cardiovascular risk factors are critical to reducing morbidity and mortality. Globally, a significant proportion of individuals with hypertension remain undiagnosed, particularly in low- and middle-income countries where health systems face limited capacity (Mills *et al.,* 2016). Community pharmacists, due to their accessibility, are uniquely positioned to close this detection gap. Evidence increasingly shows that pharmacy-based screening initiatives can identify undiagnosed hypertension, facilitate early intervention, and improve referral pathways to physicians. Several studies demonstrate the effectiveness of pharmacist-led screening. Tsuyuki *et al.,* (2015) reported that community pharmacists in Canada successfully identified patients with elevated blood pressure readings and referred them for medical follow-up, leading to improved detection rates of hypertension. Al Hamarneh *et al.,* (2013) observed similar results in Jordan, where pharmacist screenings improved case detection and patient awareness. In Morocco, Fikri Benbrahim *et al.,* (2019) confirmed that pharmacists were effective not only in identifying hypertension but also in educating patients about the importance of follow-up care. These findings highlight the potential for pharmacists to serve as the primary point of contact in cardiovascular prevention. Beyond hypertension, pharmacists have also contributed to screening for related cardiovascular risks. Hajjar *et al.,* (2014) emphasized the role of pharmacists in atrial fibrillation detection through opportunistic pulse checks and blood pressure measurements. Whelton *et al.,* (2018) noted that such early interventions reduce the risk of stroke and cardiovascular events by facilitating the timely initiation of treatment. By integrating screenings into routine pharmacy practice, pharmacists provide an accessible and cost-effective service that complements physician-led care.

Collaborative frameworks strengthen the impact of these interventions. Glynn *et al.,* (2010) demonstrated that screening, combined with structured referral systems, significantly improved treatment initiation and blood pressure control. Santschi *et al.,* (2014) reinforced this finding by demonstrating that pharmacist-led detection, followed by collaboration with general practitioners, achieved better long-term outcomes than physician care alone. Pittman *et al.,* (2019) further illustrated how integration of electronic health records and digital communication tools can enhance continuity of care, ensuring that patients identified in pharmacies receive timely medical attention. Despite these benefits, barriers persist. Limited authority to initiate treatment in some jurisdictions restricts pharmacists' ability to move beyond detection (Cheema *et al.,* 2014). Lack of standardized protocols for referral and follow-up can lead to gaps in care continuity (Khaira *et al.,* 2020). Moreover, resource constraints in low-income settings hinder the scalability of screening initiatives (WHO, 2018). Addressing these barriers requires system-wide policy reforms that formalize pharmacists' roles in detection and ensure they are supported through training, remuneration, and integrated care pathways. (Albasri *et al.,* 2020)



Pharmacist-led screening and early detection strategies have demonstrated substantial promise in addressing the global hypertension burden. By leveraging their accessibility and expertise, pharmacists can act as essential gatekeepers in cardiovascular prevention. When supported by systemic reforms and collaborative frameworks, these efforts can significantly enhance the early identification and management of hypertension, ultimately contributing to reduced disease burden at the population level.

FINDINGS AND DISCUSSION

The synthesis of evidence highlights that pharmacists can play a central role in preventing

hypertension and cardiovascular disease by supporting lifestyle modifications, facilitating early detection, and ensuring continuity of care. Across randomized controlled trials, meta-analyses, and policy reviews, a consistent pattern emerges: pharmacist-led interventions are effective, but their impact is shaped by context, system integration, and professional scope.

Lifestyle Education and Counseling

Pharmacists have demonstrated a clear capacity to influence patient behaviors linked to cardiovascular risk. Machado *et al.,*(2007) confirmed that structured pharmacist consultations improved adherence to lifestyle recommendations such as diet and exercise. Morgado *et al.,*(2011) provided evidence that pharmacist education programs enhanced patient knowledge of hypertension and increased adherence to antihypertensive regimens. Glynn *et al.,*(2010) further highlighted the effectiveness of repeated educational interactions, showing sustained reductions in blood pressure when lifestyle counseling was reinforced over time. More recent findings by Fikri Benbrahim *et al.,*(2019) demonstrated that pharmacist counseling in Morocco has successfully adapted to cultural contexts, supporting both dietary changes and patient awareness. These results indicate that lifestyle education delivered by pharmacists can yield measurable benefits when implemented systematically.

Screening and Early Detection

Early detection of hypertension remains a major global challenge, with many individuals remaining undiagnosed until complications arise (Mills et al., 2016). Evidence shows that community pharmacists can significantly improve detection rates. Tsuyuki *et al.,*(2015) demonstrated that Canadian pharmacists successfully identified elevated blood pressure and facilitated medical referrals. Al Hamarneh *et al.,*(2013) reported similar improvements in Jordan, while Hajjar *et al.,*(2014) extended the evidence by documenting the role of pharmacists in atrial fibrillation screening. These findings are supported by Santschi *et al.,*(2014), who demonstrated that collaborative pharmacist detection and follow-up with general practitioners resulted in improved long-term outcomes compared to physician care alone. Importantly, Khaira *et al.,*(2020) stressed that sustained impact requires structured referral systems and integration into multidisciplinary teams.

Barriers and Enablers

Despite strong evidence, significant barriers to implementation persist. Hajjar *et al.,*(2014) noted that limited training in behavioral counseling reduces the consistency of pharmacist interventions. Pittman *et al.,*(2019) and Albasri *et al.,*(2020) emphasized that fragmented communication between pharmacists and primary care providers undermines continuity of care. Furthermore, Cheema *et al.,*(2014) observed that pharmacists' lack of authority to initiate treatment in many jurisdictions restricts their ability to move beyond detection. On the other hand, enablers such as digital health tools and integration of electronic health records have been shown to strengthen continuity of care and monitoring (Whelton et al., 2018). Policy recognition also plays a critical role: both the World Health Organization (2018) and the National Institute for Health and Care Excellence (2019) have issued guidance supporting pharmacist involvement in cardiovascular prevention, reflecting global endorsement of their contribution. Taken together, the findings show that pharmacist-led interventions consistently improve hypertension outcomes across multiple domains. Lifestyle counseling reduces cardiovascular risk factors, while screening initiatives facilitate timely detection and referral. The strongest results are observed in settings where pharmacists are integrated into multidisciplinary teams, supported by policy frameworks, and provided with adequate training and remuneration. These findings highlight the dual role of pharmacists as both educators and frontline healthcare providers, enabling them to bridge the gap between preventive strategies and community-based care.

CONTRIBUTION TO RESEARCH

This study contributes to the growing body of evidence that positions pharmacists as pivotal actors in the prevention and early management of hypertension and cardiovascular disease. By synthesizing randomized trials, systematic reviews, and policy frameworks, it clarifies that pharmacists' contributions extend well beyond medication dispensing to encompass lifestyle education, early detection, and integration into multidisciplinary care. The analysis highlights that while clinical outcomes such as blood pressure reduction are consistently reported, systemic enablers—such as interprofessional collaboration, digital integration, and sustained policy support—determine the long-term effectiveness of pharmacist-led interventions. In this way, the research not only consolidates existing knowledge but also underscores the methodological and policy contexts necessary for scaling successful models of practice. Future research should focus on developing integrative frameworks that combine clinical, technological, and psychosocial perspectives. Badmus *et al.,* (2018) argue for secure and scalable healthcare monitoring systems through HealthDevOps models that emphasize compliance, accountability, and traceability. Applying such frameworks to pharmacist-led interventions could strengthen real-time monitoring of outcomes, ensuring reliability and scalability across diverse settings. Similarly, Fuseini *et al.,* (2022) emphasize the importance of trauma-informed care and therapeutic communication in reaching vulnerable populations. Integrating these approaches into pharmacist training could enrich their capacity to support patients whose hypertension and cardiovascular risks are shaped not only by biomedical but also by psychosocial determinants. This study makes a significant contribution by situating pharmacist-led hypertension prevention within the broader landscape of healthcare innovation and community health. It points to future

directions that embed accountability through digital systems and enhance patient-centered care through psychosocial sensitivity, ensuring that pharmacists' roles in cardiovascular disease prevention remain both effective and equitable.

CONCLUSION

Pharmacists have become indispensable contributors to the prevention and early management of hypertension and cardiovascular disease, two of the most pressing global health concerns. Evidence from randomized controlled trials and systematic reviews consistently demonstrates that pharmacist-led interventions, particularly those focusing on lifestyle education and screening, can significantly improve blood pressure outcomes, enhance medication adherence, and promote early detection of undiagnosed cases. Beyond their biomedical contributions, pharmacists provide frequent patient contact, allowing for personalized education, ongoing monitoring, and reinforcement of health-promoting behaviors. These strengths underscore their potential as frontline educators and accessible healthcare providers, particularly in underserved communities where primary care resources are limited. Nevertheless, challenges such as limited training in behavioral counseling, insufficient remuneration, and fragmented communication with physicians continue to constrain their effectiveness. Addressing these barriers through systemic reforms will be key to realizing the full potential of pharmacists in cardiovascular prevention. Looking forward, the sustainable integration of pharmacists into frameworks for hypertension and cardiovascular disease prevention will depend on leveraging both technological and psychosocial innovations. Digital platforms, such as those described by Badmus *et al.,* (2018), can embed accountability, compliance, and traceability into pharmacist-led interventions, ensuring robust monitoring and scalability across diverse healthcare systems. At the same time, the patient-centered models emphasized by Fuseini *et al.,* (2022) underscore the importance of incorporating trauma-informed care and therapeutic communication into pharmacist practice, particularly when interacting with vulnerable populations. Together, these perspectives point to a future where pharmacists' contributions are enhanced through interdisciplinary integration, ensuring that interventions not only deliver measurable clinical outcomes but also foster equity, trust, and long-term sustainability in cardiovascular disease prevention.

REFERENCES

- Albasri, A., Clark, C. E., Omboni, S., McDonagh, S., McManus, R., & Sheppard, J. P. (2020). Effective detection and management of hypertension through community pharmacy in England. *Pharmaceutical Journal*. Published online 17 March 2020. doi:10.1211/PJ.2020.20207532
- Al Hamarneh, Y. N., Hemmelgarn, B. R., Hassan, I., Tsuyuki, R. T., & Campbell, N. R. C. (2013). Community pharmacist-initiated screening for cardiovascular risk in Jordan. *Journal of Human Hypertension, 27*(9), 623–627. https://doi.org/10.1038/jhh.2013.25
- Badmus, A., Adebayo, M., & Ehigie, D. E. (2018). Secure and scalable model lifecycle management in healthcare AI: A DevOps approach for privacy, compliance, and traceability. *Scholars Journal of Medical Case Reports, 6*(12), 1087–1099. https://doi.org/10.36347/sjmcr.2018.v06i12.025
- Carter, B. L., Rogers, M., Daly, J., Zheng, S., & James, P. A. (2009). The potency of team-based care interventions for hypertension: A meta-analysis. *Archives of Internal Medicine, 169*(19), 1748–1755. https://doi.org/10.1001/archinternmed.2009.316
- Cheema, E., Sutcliffe, P., & Singer, D. R. J. (2014). The impact of interventions by pharmacists in community pharmacies on control of hypertension: A systematic review and meta-analysis of randomized controlled trials. *British Journal of Clinical Pharmacology, 78*(6), 1238–1247. https://doi.org/10.1111/bcp.12452
- Fikri Benbrahim, N., Fikri Benbrahim, O., Kettani, A., & Haddou Rahou, B. (2019). Pharmacist-led interventions for the management of hypertension in Morocco. *International Journal of Pharmacy Practice, 27*(6), 556–562. https://doi.org/10.1111/ijpp.12562
- Fuseini, F. S., Boateng, J., Osekre, E. A., & Braimoh, J. J. (2022). Enhancing mental health outcomes for adolescent and older veterans through conflict management and therapeutic communication strategies in trauma-informed care. *Social Science and Humanities Journal, 6*(4), 2687–2705. https://doi.org/10.18535/sshj.v6i04.622
- Glynn, L. G., Murphy, A. W., Smith, S. M., Schroeder, K., & Fahey, T. (2010). Interventions used to improve control of blood pressure in patients with hypertension. *Cochrane Database of Systematic Reviews, 2010*(3), CD005182. https://doi.org/10.1002/14651858.CD005182.pub4
- Hajjar, E. R., Cafiero, A. C., & Hanlon, J. T. (2014). Polypharmacy in elderly patients. *American Journal of Geriatric Pharmacotherapy, 5*(4), 345–351. https://doi.org/10.1016/j.amjopharm.2007.12.002
- Khaira, M., Mathers, A., Benny Gerard, N., Dolovich, L., & Dolovich, L. (2020). Pharmacist interventions for hypertension management: A systematic review and meta-analysis of randomized controlled trials. *Journal of Clinical Hypertension, 22*(6), 1008–1019. https://doi.org/10.1111/jch.13875
- Machado, M., Bajcar, J., Guzzo, G. C., & Einarson, T. R. (2007). Sensitivity of patient outcomes to pharmacist interventions. *Part I: Systematic review and meta-analysis in hypertension management*.

Annals of Pharmacotherapy, 41(10), 1569–1581. https://doi.org/10.1345/aph.1K311

- Mills, K. T., Bundy, J. D., Kelly, T. N., Reed, J. E., Kearney, P. M., Reynolds, K., Chen, J., & He, J. (2016). Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. *Circulation, 134*(6), 441–450. https://doi.org/10.1161/CIRCULATIONAHA.115.018912
- Morgado, M., Rolo, S., Castelo-Branco, M., & Alves, G. (2011). Pharmacist interventions to enhance blood pressure control and adherence in patients with hypertension. *American Journal of Health-System Pharmacy, 68*(7), 563–570. https://doi.org/10.2146/ajhp090563
- National Institute for Health and Care Excellence (NICE). (2019). Hypertension in adults: Diagnosis and management (NICE Guideline NG136). https://www.nice.org.uk/guidance/ng136
- Pittman, D. G., Chen, W., Bowlin, S. J., & Foody, J. M. (2019). Adherence to antihypertensive medication in patients with comorbid conditions. *Journal of Managed Care & Specialty Pharmacy, 25*(9), 994–1002. https://doi.org/10.18553/jmcp.2019.18374
- Santschi, V., Chiolero, A., Colosimo, A. L., Platt, R. W., Taffé, P., Burnand, B., & Paradis, G. (2014). Improving blood pressure control through pharmacist interventions: A meta-analysis of randomized controlled trials. *Journal of the American Heart Association, 3*(2), e000718. https://doi.org/10.1161/JAHA.113.000718
- Tan, E. C. K., Stewart, K., Elliott, R. A., & George, J. (2016). Pharmacist services for hypertension management: A systematic review and meta-analysis. *Journal of Human Hypertension, 30*(6), 341–352. https://doi.org/10.1038/jhh.2015.97
- Tsuyuki, R. T., Al Hamarneh, Y. N., Jones, C. A., & Hemmelgarn, B. R. (2015). The effectiveness of pharmacist interventions on cardiovascular risk: The Alberta Vascular Risk Reduction Community Pharmacy Project. *Circulation, 132*(2), 93–100. https://doi.org/10.1161/CIRCULATIONAHA.114.012007.
- Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Himmelfarb, C. D., … Wright, J. T. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. *Hypertension, 71*(6), e13–e115. https://doi.org/10.1161/HYP.0000000000000065
- World Health Organization. (2018). *HEARTS technical package for cardiovascular disease management in primary health care: Education module*. Geneva: WHO. https://www.who.int/publications/i/item/who-hearts

Cite This Article: Hudallah Oluwakemi Adetola, Chinwe Ann ILOABANAFO, Sakiru Ayobami Hamzat, Latifat Abolore Igbin (2023). Pharmacists as Frontline Health Educators: Strategies for Hypertension and Cardiovascular Disease Prevention. *EAS J Pharm Pharmacol, 5*(6), 176-183.